Spotlight
Topic
Brand Insights
Subscribe
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Health Plan Premiums: Pharma Takes the Blame
Article
Pharmaceutical Executive
Pharmaceutical ExecutivePharmaceutical Executive-10-01-2001
Volume 0
Issue 0
Menlo Park, California-Premiums for employer-sponsored health insurance jumped 11 percent from spring 2000 to spring 2001-the biggest increase since 1992-and payers blame that huge spike on pharmaceutical expenditures.
Articles in this issue
National Crisis Supercedes Coverage Debate
PBMs: Merck-Medco in the Hot Seat
AIDS Treatments: Discounts Here to Stay
Chaotic Content: Streamlined Solutions
Clinical Trial: FDA Stays Silent on Trovan Charges
National Crisis Supercedes Coverage Debate
A Five-Year Forecast: Clear Seas Ahead?
Weak Bones, Strong Market
Approvals: Novartis’ Silver Lining
Pfizer and others Pitch In
Oncology: EMEA Approval Lags
BioTech's New Business Model
Illegal Sales in India
Also Known As...The Value of Generic Names
Health Plan Premiums: Pharma Takes the Blame
Recent Videos
Related Content
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Podcast
Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
